{
    "2020-11-06": [
        [
            {
                "time": "",
                "original_text": "下周588亿市值限售股解禁，环比减少53.99% 解禁",
                "features": {
                    "keywords": [
                        "限售股",
                        "解禁",
                        "市值"
                    ],
                    "sentiment_score": -0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "金融"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "",
                "original_text": "药明康德(02359)获股东WuXi AppTec(BVI) Inc.合计减持2310.66万股A股 减持股份",
                "features": {
                    "keywords": [
                        "药明康德",
                        "减持",
                        "股东"
                    ],
                    "sentiment_score": -0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药生物"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "",
                "original_text": "医药生物行业周报：海外疫情持续爆发 医疗服务领涨",
                "features": {
                    "keywords": [
                        "医药生物",
                        "疫情",
                        "医疗服务"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药生物"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "药明康德(603259.SH)：WuXi AppTec(BVI) Inc.累计减持2310.66万股减持计划实施完毕 拟减持股份",
                "features": {
                    "keywords": [
                        "药明康德",
                        "减持",
                        "股东"
                    ],
                    "sentiment_score": -0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药生物"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "",
                "original_text": "药明康德：WuXi AppTec (BVI) Inc.减持0.95%股份，减持计划实施完毕 拟减持股份",
                "features": {
                    "keywords": [
                        "药明康德",
                        "减持",
                        "股东"
                    ],
                    "sentiment_score": -0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药生物"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "",
                "original_text": "【泰有财·研究服务】医药行业点评",
                "features": {
                    "keywords": [
                        "医药",
                        "点评"
                    ],
                    "sentiment_score": 0.0,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药生物"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "",
                "original_text": "医药2021年度策略：不畏浮云遮望眼",
                "features": {
                    "keywords": [
                        "医药",
                        "策略"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药生物"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "",
                "original_text": "南北互联互通月报：北上余额先升后降 南下持续买入",
                "features": {
                    "keywords": [
                        "南北互联互通",
                        "北上",
                        "南下"
                    ],
                    "sentiment_score": 0.3,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "金融"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "医药行业2021年投资策略：“双循环”背景下 “创新升级＋进口替代”引领医药大时代",
                "features": {
                    "keywords": [
                        "医药",
                        "双循环",
                        "创新升级",
                        "进口替代"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "true",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药生物"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "药明康德(603259)2020年三季报点评：20Q3业绩超预期 海外订单转移有望持续兑现",
                "features": {
                    "keywords": [
                        "药明康德",
                        "三季报",
                        "业绩",
                        "海外订单"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药生物"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "生物医药行业点评：全国冠脉支架带量采购落地 医疗器械进入创新时代",
                "features": {
                    "keywords": [
                        "生物医药",
                        "冠脉支架",
                        "带量采购",
                        "医疗器械"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "true",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药生物"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "获默沙东、基石药业青睐，ROR1为何成为抗癌新兴靶点？",
                "features": {
                    "keywords": [
                        "默沙东",
                        "基石药业",
                        "ROR1",
                        "抗癌"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药生物"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            }
        ]
    ]
}